Get the Stockscreener App
11.10
2.29%
-0.26
After Hours:
11.10
Alvotech Stock (ALVO) Latest News
Alvotech is Now Oversold (ALVO) - Nasdaq
Pharmaceutical firms launch Stelara biosimilars - Drug Store News
FDA accepts Alvotech, Teva's BLA for proposed Eylea biosimilar - Drug Store News
Is Alvotech (ALVO) the Best Low Price Pharma Stock to Invest In Right Now? - Yahoo Canada Finance
Alvotech (NASDAQ:ALVO) Shares Up 5.5%Time to Buy? - MarketBeat
12 Best Low Price Pharma Stocks To Invest In Right Now - Insider Monkey
Alvotech to Report Full Year Financial Results for 2024 on - GlobeNewswire
Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET - The Manila Times
Alvotech Launches SELARSDI Biosimilar in U.S. Market - TipRanks
Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðung - GlobeNewswire
When Will Alvotech Reveal Its 2024 Performance? Key Dates for Investors - StockTitan
Teva and Alvotech launch ustekinumab biosimilar injection in US - Yahoo Finance
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US - MSN
Teva/Alvotech follow Amgen in launching biosimilar for J&J’s Stelara - MSN
Alvotech (NASDAQ:ALVO) Shares Down 6.7%Here's What Happened - MarketBeat
Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea - MSN
Teva, Alvotech Launch SELARSDI, Stelara Biosimilar - Contract Pharma
Teva Pharma and Alvotech launch US biosimilar to J&J’s Stelara - PharmaLive
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara - MSN
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. - The Korea Bizwire
Teva, Alvotech announces U.S. availability of SELARSDI injection - TipRanks
Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara -February 21, 2025 at 06:27 am EST - Marketscreener.com
Alvotech og Teva tilkynna að sala er hafin í Bandaríkjunum - GlobeNewswire
Teva And Alvotech Announce Selarsdi(TM) Injection Now Available In The U.S. -February 21, 2025 at 06:07 am EST - Marketscreener.com
Teva Pharma and Alvotech launch Stelara biosimilar in US -February 21, 2025 at 06:09 am EST - Marketscreener.com
Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance - Insights
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea - MSN
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea - Marketscreener.com
Teva and Alvotech advance biosimilar portfolio in USA - The Pharma Letter
FDA accepts BLA for Alvotech’s Eylea biosimilar AVT06 review - World Pharmaceutical Frontiers
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar - Managed Healthcare Executive
Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea (TEVA:NYSE) - Seeking Alpha
FDA Accepts Alvotech’s Eylea Biosimilar for Review - Contract Pharma
Alvotech’s AVT06 Biosimilar Application Accepted by FDA - TipRanks
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept) - Marketscreener.com
US FDA Accepts Alvotech, Teva's Biologics License Application for Eylea Biosimilar - Marketscreener.com
Alvotech and Teva’s BLA filing for AVT06 accepted by FDA - TipRanks
FDA To Review BLA For Alvotech's Proposed Biosimilar To EyleaQuick Facts - Nasdaq
Alvotech and Teva Pharmaceuticals Announce FDA Acceptance of Biologics License Application for AVT06, a Biosimilar Candidate to Eylea - Nasdaq
Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application - Marketscreener.com
Alvotech and Teva Announce Filing Acceptance of U.S. - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) - Finansavisen
Alvotech (NASDAQ:ALVO) Now Covered by Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Alvotech (ICSE:ALVO) with Buy Recommendation - Nasdaq
UBS maintains Alvotech stock Buy rating, $18 target By Investing.com - Investing.com Australia
UBS Initiates Coverage of Alvotech (ALVO) with Buy Recommendation - MSN
1.25%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):